Treatment adherence in psoriatic patients during COVID‐19 pandemic: Real‐world data from a tertiary hospital in Greece
| Autor: | N. Sideris, Aimilios Lallas, Elena Sotiriou, Demetrios Ioannides, F. Vrani, K Bakirtzi, Ilias Papadimitriou, E. Vakirlis |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Coronavirus disease 2019 (COVID-19) Treatment adherence coronavirus MEDLINE Disease Dermatology 030230 surgery Letter to Editor Medication Adherence Tertiary Care Centers 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine COVID‐19 psoriatic treatment Psoriasis Pandemic medicine Humans adherence Letters to Editor Intensive care medicine Pandemics Aged Aged 80 and over Greece SARS-CoV-2 business.industry Public health COVID-19 psoriasis Middle Aged medicine.disease Infectious Diseases Female Observational study business |
| Zdroj: | Journal of the European Academy of Dermatology and Venereology |
| ISSN: | 1468-3083 0926-9959 |
| DOI: | 10.1111/jdv.16759 |
| Popis: | COVID‐19 pandemic raised questions both in dermatologists and in patients about the use of immunosuppressive medications. Although dermatologic societies recommend the continuing of psoriatic systemic therapies and biologics, little is known about treatment adherence in psoriatic patients during COVID‐19 outbreak. Medication self‐management may feel burdensome to patients with psoriasis due to the nature of treatments and many of them face additional challenges as they may suffer from comorbidities. Under these already difficult conditions, COVID‐19 disease puts extra pressure on individuals and may undermine adherence. Acknowledging treatment non‐adherence as a consequence of conflicting goals may help to find the reasons for but, most important, solutions to non‐adherence especially during public health crises. The objective of our study was to evaluate the adherence of psoriatic patients in traditional systemic treatment as well as biologics and identify possible influencing factors of drug interruption during COVID‐10 pandemic. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text